Passage Bio Stock Forecast, Price & News

Passage Bio (NASDAQ:PASG) Frequently Asked Questions

Is Passage Bio a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Passage Bio in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Passage Bio stock.
View analyst ratings for Passage Bio or view top-rated stocks.

How has Passage Bio's stock price been impacted by COVID-19?

Passage Bio's stock was trading at $18.86 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PASG shares have decreased by 61.9% and is now trading at $7.18.
View which stocks have been most impacted by COVID-19.

When is Passage Bio's next earnings date?

Passage Bio is scheduled to release its next quarterly earnings announcement on Wednesday, March 2nd 2022.
View our earnings forecast for Passage Bio.

How were Passage Bio's earnings last quarter?

Passage Bio, Inc. (NASDAQ:PASG) posted its earnings results on Thursday, November, 4th. The company reported ($0.87) earnings per share for the quarter, missing analysts' consensus estimates of ($0.80) by $0.07. During the same quarter last year, the company earned ($0.63) EPS.
View Passage Bio's earnings history.

What price target have analysts set for PASG?

8 equities research analysts have issued 1-year price targets for Passage Bio's stock. Their forecasts range from $2.21 to $45.00. On average, they expect Passage Bio's share price to reach $27.03 in the next twelve months. This suggests a possible upside of 276.4% from the stock's current price.
View analysts' price targets for Passage Bio or view top-rated stocks among Wall Street analysts.

Who are Passage Bio's key executives?

Passage Bio's management team includes the following people:

• Dr. Bruce A. Goldsmith M.B.A., Ph.D., CEO, Pres & Director (Age 55, Pay $756.92k)
• Ms. Jill M. Quigley Esq., J.D., Chief Operating Officer (Age 45, Pay $997.67k)
• Dr. James M. Wilson M.D., Ph.D., Co-Founder & Chief Scientific Advisor (Age 66)
• Mr. Alexandros Fotopoulos MSc, MBA, Chief Technical Officer (Age 52)
• Mr. Stuart M. Henderson, VP Investor Relations & Strategic Fin.
• Mr. Edgar B. Cale Esq., J.D., Gen. Counsel & Company Sec. (Age 57)
• Robin DeRogatis, VP HR
• Dr. Eliseo Oreste Salinas, Chief R&D Officer and Interim Chief Medical Officer (Age 65)

Who are some of Passage Bio's key competitors?

Some companies that are related to Passage Bio include Sorrento Therapeutics (SRNE), Krystal Biotech (KRYS), Atara Biotherapeutics (ATRA), Inhibrx (INBX), Coherus BioSciences (CHRS), REGENXBIO (RGNX), Replimune Group (REPL), Immunocore (IMCR), iTeos Therapeutics (ITOS), Sangamo Therapeutics (SGMO), Ocugen (OCGN), AlloVir (ALVR), Rubius Therapeutics (RUBY), Humacyte (HUMA) and Caribou Biosciences (CRBU).
View all of PASG's competitors.

What other stocks do shareholders of Passage Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Passage Bio investors own include Alector (ALEC), NVIDIA (NVDA), Advanced Micro Devices (AMD), DocuSign (DOCU), Intel (INTC), Alteryx (AYX), Gossamer Bio (GOSS), JD.com (JD), Micron Technology (MU) and Black Diamond Therapeutics (BDTX).

When did Passage Bio IPO?

(PASG) raised $126 million in an initial public offering (IPO) on Friday, February 28th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Chardan was co-manager.

What is Passage Bio's stock symbol?

Passage Bio trades on the NASDAQ under the ticker symbol "PASG."

Who are Passage Bio's major shareholders?

Passage Bio's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.76%), Morgan Stanley (2.11%), Geode Capital Management LLC (0.87%), Wellington Management Group LLP (0.78%), Millennium Management LLC (0.64%) and Bank of New York Mellon Corp (0.58%). Company insiders that own Passage Bio stock include Alexandros Fotopoulos, Athena Countouriotis, Bruce A Goldsmith, Gary Romano, Jill M Quigley, Life Sciences Ix LP Frazier, Richard Steven Morris and Thomas Woiwode.
View institutional ownership trends for Passage Bio.

Which institutional investors are selling Passage Bio stock?

PASG stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Marshall Wace LLP, Citigroup Inc., Geode Capital Management LLC, Cubist Systematic Strategies LLC, California State Teachers Retirement System, Squarepoint Ops LLC, and New York State Common Retirement Fund. Company insiders that have sold Passage Bio company stock in the last year include Gary Romano, and Jill M Quigley.
View insider buying and selling activity for Passage Bio or view top insider-selling stocks.

Which institutional investors are buying Passage Bio stock?

PASG stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Two Sigma Advisers LP, Two Sigma Investments LP, Renaissance Technologies LLC, Wellington Management Group LLP, SG Americas Securities LLC, Trexquant Investment LP, and Goldman Sachs Group Inc.. Company insiders that have bought Passage Bio stock in the last two years include Alexandros Fotopoulos, Athena Countouriotis, Bruce A Goldsmith, Jill M Quigley, Life Sciences Ix LP Frazier, Richard Steven Morris, and Thomas Woiwode.
View insider buying and selling activity for Passage Bio or or view top insider-buying stocks.

How do I buy shares of Passage Bio?

Shares of PASG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Passage Bio's stock price today?

One share of PASG stock can currently be purchased for approximately $7.18.

How much money does Passage Bio make?

Passage Bio has a market capitalization of $388.49 million. The company earns $-112.23 million in net income (profit) each year or ($3.38) on an earnings per share basis.

How many employees does Passage Bio have?

Passage Bio employs 74 workers across the globe.

What is Passage Bio's official website?

The official website for Passage Bio is www.passagebio.com.

Where are Passage Bio's headquarters?

Passage Bio is headquartered at TWO COMMERCE SQUARE 2001 MARKET STREET 28TH FLOOR, PHILADELPHIA PA, 19103.

How can I contact Passage Bio?

Passage Bio's mailing address is TWO COMMERCE SQUARE 2001 MARKET STREET 28TH FLOOR, PHILADELPHIA PA, 19103. The company can be reached via phone at 267-866-0311 or via email at [email protected].